Want to see SE:NEOLA full AI Analyst Report?
NEOLA Stock Chart & Stats
kr0.58
kr0.02(3.45%)
At close: 4:00 PM EDT
kr0.58
kr0.02(3.45%)
Day’s Range― - ―
52-Week Rangekr0.45 - kr2.18
Previous CloseN/A
Volume49.06K
Average Volume (3M)140.64K
Market Cap
kr50.16M
Enterprise Valuekr64.18M
Total Cash (Recent Filing)kr16.12M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.36
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding110,476,940
10 Day Avg. Volume61,685
30 Day Avg. Volume140,641
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet reduces interest and refinancing pressure while preserving financial flexibility. The substantial equity base gives Neola more capacity to continue product development and pursue commercialization without the additional constraints that leverage would impose.
Focused Neonatal Monitoring PropositionNeola is focused on a defined clinical need in neonatal care rather than operating across unrelated markets. A device aimed at continuous, non-invasive monitoring of newborn breathing could support a clear clinical use case if development and adoption progress successfully.
Losses Have Not Sharply AcceleratedRelative stability in losses provides some evidence that spending has not entered an uncontrolled expansion phase, despite the company remaining unprofitable. Maintaining a broadly consistent cost trajectory can preserve planning flexibility while Neola works toward a commercially scalable product.
Bears Say
No Meaningful Revenue BaseA near-zero revenue base indicates that Neola has not yet established meaningful commercial traction. Until product sales generate recurring operating income, the business remains dependent on external funding and cannot demonstrate that its neonatal monitoring proposition can scale economically.
Persistent Operating LossesPersistent net, EBITDA, and EBIT losses show that the current operating model does not yet support profitability. Continued losses can erode the equity base over time and increase the importance of achieving meaningful revenue growth or securing additional financing.
Ongoing Cash BurnNegative operating cash flow confirms that the core business is not self-funding and that cash resources are being consumed to sustain operations. This weakens financial durability because progress toward commercialization must occur before funding needs place greater pressure on the company.
Neola Medical AB News
NEOLA FAQ
What was Neola Medical AB’s price range in the past 12 months?
Neola Medical AB lowest stock price was kr0.45 and its highest was kr2.18 in the past 12 months.
What is Neola Medical AB’s market cap?
Neola Medical AB’s market cap is kr50.16M.
When is Neola Medical AB’s upcoming earnings report date?
Neola Medical AB’s upcoming earnings report date is Nov 18, 2026 which is in 36 days.
How were Neola Medical AB’s earnings last quarter?
Neola Medical AB released its earnings results on Aug 20, 2026. The company reported -kr0.048 earnings per share for the quarter.
Is Neola Medical AB overvalued?
According to Wall Street analysts Neola Medical AB’s price is currently Overvalued.
Does Neola Medical AB pay dividends?
Neola Medical AB does not currently pay dividends.
What is Neola Medical AB’s EPS estimate?
Neola Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neola Medical AB have?
Neola Medical AB has 110,476,940 shares outstanding.
What happened to Neola Medical AB’s price movement after its last earnings report?
Neola Medical AB reported an EPS of -kr0.048 in its last earnings report. Following the earnings report the stock price went down -9.009%.
Which hedge fund is a major shareholder of Neola Medical AB?
Currently, no hedge funds are holding shares in SE:NEOLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neola Medical AB
Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. This device facilitates ongoing lung function monitoring and generates immediate alerts for critical, life-threatening complications. It achieves this by accurately tracking changes in lung volume and oxygen gas concentration. The ultimate goal of NEOLA is to enhance intensive care and promote healthier outcomes for infants born preterm. The company, formerly known as GPX Medical AB, officially changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was established in 2016 and is headquartered in Lund, Sweden.